CTF1 and RAPGEF3 were previously reported to be parts of gene signatures related to tumor microenvironment and immune system [26,30], with the first seen downregulated and methylated in BAP1 mutated samples [36]; PALMD was found to have low expression in metastatic UM tissues [37], and GSTA3 in low-survival patients [38]. Here, RAPGEF3 is linked to neoplasm.